<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141010</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus</dc:title>
<dc:description xml:lang="en">In this study, we review the efficacy and safety limitations of insulin-dependent oral antidiabetic agents. In terms of efficiency, the main drawback of metformin, sulfonylureas, gliptins and -to a lesser extent- glitazones is durability. No drug per se is able to maintain stable blood glucose control for years. Metformin, sulfonylureas and gliptins have demonstrated safety. Experience with the first two drug groups is more extensive. The main adverse effect of metformin is gastrointestinal discomfort. Major concerns related to the use of sulfonylureas are hypoglycemia and weight gain. The use of pioglitazone has been associated with an increased risk of bladder cancer, edema, heart failure, weight gain, and distal bone fractures in postmenopausal women. The most common adverse reactions associated with glucagon-like peptide-1 agonists are gastrointestinal discomfort that sometimes leads to treatment discontinuation (AU)</dc:description>
<dc:creator>Pablos-Velasco, Pedro L de</dc:creator>
<dc:creator>Fuente Valerón, Pino</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En este trabajo se revisan las limitaciones en relación con la eficacia y la seguridad de los antidiabéticos orales cuyo efecto depende de la insulina. En términos de eficacia, el principal inconveniente de la metformina, las sulfonilureas, las gliptinas y, en menor medida, las TZD es la durabilidad. Ningún fármaco "per se" es capaz de mantener un control glucémico estable durante años. En relación con la seguridad, metformina, sulfonilureas y gliptinas han demostrado ser fármacos seguros. Hay una experiencia más dilatada con los 2 primeros grupos. El principal efecto adverso de la metformina son las molestias gastrointestinales. La hipoglucemia y el aumento de peso son las complicaciones más importantes relacionadas con el uso de sulfonilureas. El uso de pioglitazona se ha asociado a aumento en el riesgo de padecer cáncer de vejiga, edema, insuficiencia cardíaca, aumento de peso y fracturas óseas distales en mujeres posmenopáusicas. Las reacciones adversas más frecuentes asociadas a los agonistas de GLP-1 son las digestivas, que en ocasiones obligan a interrumpir el tratamiento (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);141(supl.2): 20-25, nov. 2013. tab</dc:source>
<dc:identifier>ibc-141010</dc:identifier>
<dc:title xml:lang="es">Limitaciones de los fármacos dependientes de insulina para el tratamiento de la diabetes mellitus tipo 2</dc:title>
<dc:subject>^d3946^s22057</dc:subject>
<dc:subject>^d3946^s22032</dc:subject>
<dc:subject>^d7182^s22011</dc:subject>
<dc:subject>^d4420</dc:subject>
<dc:subject>^d5908^s22036</dc:subject>
<dc:subject>^d7182^s22078</dc:subject>
<dc:subject>^d7181^s22036</dc:subject>
<dc:subject>^d23861</dc:subject>
<dc:subject>^d22231</dc:subject>
<dc:subject>^d7500^s22063</dc:subject>
<dc:subject>^d50567^s32387</dc:subject>
<dc:subject>^d13841^s22020</dc:subject>
<dc:subject>^d8862^s22020</dc:subject>
<dc:subject>^d38089^s22020</dc:subject>
<dc:subject>^d7182^s22020</dc:subject>
<dc:subject>^d6486^s22036</dc:subject>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d52843^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5732^s22036</dc:subject>
<dc:subject>^d52843^s22078</dc:subject>
<dc:subject>^d1774^s22036</dc:subject>
<dc:subject>^d4419</dc:subject>
<dc:subject>^d13841^s22078</dc:subject>
<dc:subject>^d13841^s22073</dc:subject>
<dc:subject>^d8862^s22073</dc:subject>
<dc:subject>^d38089^s22073</dc:subject>
<dc:subject>^d7182^s22073</dc:subject>
<dc:subject>^d8862^s28898</dc:subject>
<dc:subject>^d38089^s22078</dc:subject>
<dc:type>article</dc:type>
<dc:date>201311</dc:date>
</metadata>
</record>
</ibecs-document>
